RESEARCH

Urinary estrogen metabolites and breast cancer risk in Chinese population

Xiaomin Li1,*, Ling Fang2,*, Hongjiang Li1 and Xiaoqin Yang1

1Department of Breast Surgery, West China Hospital, Sichuan University, Chengdu, China
2Department of Breast Surgery, Cheng Du Shang Jin Nan Fu Hospital, West China Hospital, Sichuan University, Chengdu, China

Correspondence should be addressed to X Yang: xiaoqinyang2019@outlook.com

*(X Li and L Fang contributed equally to this work)

Abstract

Background: In China, the association between estrogen metabolism and breast cancer risk and the differences in metabolic pattern between breast cancer patients and controls are poorly understood.

Methods: A total of 84 patients with invasive breast cancer and 47 controls with benign breast diseases were included in this study. Estrogen metabolites from their morning urine were determined by HPLC-MS/MS and evaluated in both groups, and the predictive value of each estrogen metabolite in the malignant group according to their menstrual status was analyzed.

Results: Urinary concentration of estrogen metabolites 2-hydroxyestrone (2-OHE1), 2-hydroxyestradiol (2-OHE2), 4-hydroxyestradiol (4-OHE2), 4-methoxyestrone (4-MeOE1), and 16α-hydroxyestrone were lower in postmenopausal patients with breast cancer, compared with benign controls. In logistic regression model, breast cancer risk increased with the decline in the levels of 4-OHE2 and 4-MeOE1. In premenopausal patients, a difference in the level of 2-OHE2 was observed between both groups, and 2-OHE2 was found to have predictive value for breast cancer. Additionally, urinary 2-OHE2 level in premenopausal hormone receptor positive (HR+) patients was considerably higher compared with hormone receptor negative patients.

Conclusions: We found that lower urinary levels of 4-OHE2 and 4-MeOE1 had predictive value for breast cancer, and higher 2-OHE1 were associated with HR+ breast cancer in premenopausal women.

Introduction

Breast cancer is a malignant tumor that occurs in the mammary gland. It is the leading female malignant tumor, posing a major threat to women’s health globally. However, the incidence of breast cancer worldwide, including China, has gradually increased recently (1, 2).

In patients with breast cancer, abnormalities occur in estrogen metabolism, in particular in the level of estrogen and their metabolites. Hydroxylation of the carbon atoms at positions 2, 4, and 16 of the steroid ring of estrogen produces a cascade of metabolites with diverse biological properties, such as 2-hydroxyestrone (2-OHE1), 4-hydroxyestrone (4-OHE1), and 16α-hydroxyestrone (16α-OHE1). These hydroxylated metabolites can be further methylated into less toxic methoxy derivatives or oxidized into mutagenic quinone adducts (3, 4, 5). Estrogen and their metabolites are considered to be one of the most important factors affecting breast cancer risk (6, 7). By binding to its corresponding estrogen receptor (ER), estrogen can activate the receptor signaling pathways to promote cell growth, proliferation, and endometrial...
hyperplasia, ultimately leading to the occurrence of cancer (8, 9, 10). Estrogen metabolites cause noticeably different effects: 2-OHE1 and 2-hydroxyestradiol (2-OHE2), as tumor suppressors, can inhibit breast cancer cell growth and proliferation by reducing the binding affinity to the ER, in contrast to 16α-OHE1 which has a very strong affinity to the ER with potential genotoxic damage (11, 12, 13, 14, 15).

Previous epidemiological studies of estrogen metabolism have been limited and were conducted using RIA and ELISA which have poor specificity, accuracy, and/or reproducibility (16, 17, 18, 19). HPLC coupled with MS makes more sensitive, specific, and accurate epidemiological studies possible (20, 21, 22, 23, 24, 25, 26).

Recently, we developed a rapid quantitative HPLC-MS/MS method that can simultaneously detect estrogen and their metabolites with high specificity (27). In this study, we used this method to determine estrogens and estrogen metabolites in the urine of patients with breast cancer and fibroadenoma, a benign breast disease. The association between ER status and estrogen metabolism in breast cancer was also analyzed.

Methods

Patients and samples

From January 2019 to September 2019, we collected morning urine samples from 84 invasive breast cancer patients and 47 breast fibroadenoma patients, in the Department of Breast Surgery, West China Hospital, Sichuan University. The inclusion criteria were as follows: (1) female patients aged 18–75 years old; (2) diagnosed with primary invasive breast cancer by core needle biopsy or diagnosed with fibroadenoma clinically; (3) have not received medical treatment of exogenous estrogen or progestin; (4) have not received systemic breast cancer-related treatment; and (5) have normal liver and kidney function. We excluded patients receiving exogenous estrogen or progestin or systemic treatment, exhibiting abnormal liver or kidney function, or diagnosed with another cancer, with endocrine disease, with ovary disease or pregnancy.

The morning urine samples were collected at the time of diagnosis for postmenopausal patients or on the 7th day in the menstrual cycle for premenopausal patients. ER positivity or progesterone receptor positivity was defined as both ≥1% positive tumor cells with nuclear staining.

The study was approved by the Ethics Commission of West China Hospital of Sichuan University, and every participant signed an informed consent.

Laboratory assay

In urine, endogenous estrogens (estradiol and estrone) and their metabolites are present primarily in a conjugated form. Based on the criteria previously described, prior to sample analysis, a hydrolysis step is required to release endogenous estrogens and their metabolites in urine. Glucuronide and sulfate moieties were removed, allowing for the measurement of total levels of each estrogen and estrogen metabolite.

HPLC-MS/MS analysis was performed using a LCMS-8050 Triple Quadrupole Liquid Chromatography Mass Spectrometry system (Shimadzu, Kyoto, Japan) to measure estrogens and metabolites in urine samples (27). Quantification of estrogens and metabolites was carried out using LabSolutions software (Shimadzu). Molar quantities were standardized to creatinine accordingly.

Statistical analysis

Data were analyzed using SPSS version 25.0 (IBM). The chi-squared test was used to assess the association between breast diseases and the clinicopathological parameters of patients. The Mann–Whitney U test was applied for the comparison of estrogen metabolites between breast cancer and benign controls, and between patients who were hormone receptor (HR) positive or negative. Logistic regression was used to assess the association of estrogen metabolites that displayed significant differences between pairwise groups with breast cancer risk. The predictive value of estrogen metabolite for breast cancer was evaluated by receiver operating characteristic (ROC) curve.

Results

Baseline characteristics of patients

We analyzed 131 patients, including 84 diagnosed with invasive breast cancer and 47 diagnosed with breast fibroadenoma. The baseline characteristics of all patients are presented in Table 1, showing the association between the two groups in clinicopathological parameters. There were no significant differences between both groups in menstrual status and history of past illnesses (family history of breast cancer, history of smoking, or history

| Table 1 | Baseline characteristics of patients |
|---------|-------------------------------------|
| Variable | Values (n) |
| Age (years) | 50.2 ± 10.3 |
| Menopausal status | 46 (58.0%) postmenopausal, 35 (42.0%) premenopausal |
| History of breast cancer | 32 (41.0%) |
| History of smoking | 10 (13.0%) |
| History of past illnesses | 67 (83.0%) |
| ER status | 57 (74.0%) ER positive, 34 (44.0%) ER negative |
| PR status | 64 (82.0%) PR positive, 37 (48.0%) PR negative |
| Hormone receptor status | 91 (79.0%) HR positive, 40 (52.0%) HR negative |

https://ec.bioscientifica.com
https://doi.org/10.1530/EC-21-0226
© 2021 The authors
Published by Bioscientifica Ltd
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
of alcohol consumption. We found that patients with increased age (P=0.005) or BMI (P = 0.003) were more likely to have breast cancer.

**Estrogen metabolism in breast cancer and fibroadenoma patients**

Due to the decrease in the levels of estrogen metabolites following menopause, cases were divided into premenopausal and postmenopausal groups for further analysis. The urinary concentrations of estradiol and estrone (parent estrogens) and their estrogen metabolites were compared in pre- or postmenopausal patients with breast cancer and breast fibroadenoma, respectively, and are presented in Tables 2 and 3. In postmenopausal patients (Table 3), the urinary levels of 2-OHE1 (P=0.029), 2-OHE2 (P=0.006), 4-OHE2 (P < 0.001), 4-methoxyestrone (4-MeOE1) (P < 0.001), and 16α-OHE1 (P < 0.001) in patients with breast cancer were remarkably lower compared with breast fibroadenoma counterparts. In premenopausal patients (Table 2), there was a significant difference in the urinary level of 2-OHE2 (P = 0.022) between the two groups.

From the logistic regression analysis (Fig. 1), we found that 4-OHE2 and 4-MeOE1 were independent predictors for breast cancer risk. Patients with ≤0.085 ng/mg urinary 4-OHE2 and ≤0.115 ng/mg urinary 4-MeOE1 had a 9.9 and 8.5% reduced risk of developing breast cancer, respectively, compared with their counterparts. ROC analysis revealed that the levels of urinary 2-OHE1, 2-OHE2, 4-OHE2, 4-MeOE1, and 16α-OHE1 in postmenopausal patients (Fig. 2) had predictive value for breast cancer, with the optimal cutoffs of 0.425, 0.415, 0.085, 0.115, and 0.345, respectively.

**Table 1** Baseline characteristics.

| Characteristic            | Cases | Controls | P     |
|---------------------------|-------|----------|-------|
| Age (years)               |       |          |       |
| <55                       | 52    | 40       | 0.005 |
| ≥55                       | 32    | 7        |       |
| BMI (kg/m²)               |       |          |       |
| <25                       | 48    | 39       | 0.003 |
| ≥25                       | 36    | 8        |       |
| Menopause                 |       |          | 0.611 |
| No                        | 39    | 24       |       |
| Yes                       | 45    | 23       |       |
| HR status                 |       |          |       |
| Positive                  | 66    |          |       |
| Negative                  | 18    |          |       |
| Molecular subtype         |       |          |       |
| Luminal A BC              | 17    |          |       |
| Luminal B BC              | 49    |          |       |
| HER2-enriched             | 10    |          |       |
| TNBC                      | 8     |          |       |
| Family history of breast cancer | 1.000 |       |       |
| No                        | 78    | 44       |       |
| Yes                       | 6     | 3        |       |
| History of smoking        |       |          | 1.000 |
| No                        | 76    | 43       |       |
| Yes                       | 8     | 4        |       |
| History of alcohol consumption | 1.000 |       |       |
| No                        | 77    | 43       |       |
| Yes                       | 7     | 4        |       |

Cases, invasive breast cancer; Controls, breast fibroadenoma; HR, hormone receptor; Luminal A BC, hormone receptor positive (ER and/or PR positive), HER2 negative, and Ki-67 low; Luminal B BC, hormone receptor positive (ER and/or PR positive), and either HER2 positive or HER2 negative with high levels of Ki-67; HER2-enriched, hormone receptor negative (ER and PR negative) and HER2 positive; TNBC, triple-negative breast cancer.

Bold indicates statistical significance, P < 0.05.

**Table 2** Estrogen metabolism in premenopausal patients.

| Estrogens and estrogen metabolites | Invasive breast cancer 50th (25th, 75th) | Breast fibroadenoma 50th (25th, 75th) | P     |
|-----------------------------------|----------------------------------------|--------------------------------------|-------|
| Parent estrogens                  | 6.35 (4.29, 8.78)                      | 4.45 (3.09, 8.59)                    | 0.420 |
| Estrone                           | 4.09 (3.03, 5.29)                      | 4.32 (2.79, 8.01)                    | 0.466 |
| Estradiol                         | 2.04 (1.44, 3.84)                      | 2.81 (1.54, 4.54)                    | 0.305 |
| 2-Hydroxylation pathway           | 1.90 (1.21, 3.57)                      | 3.11 (1.86, 6.19)                    | 0.065 |
| 2-OHE1                            | 1.03 (0.51, 2.49)                      | 1.49 (0.56, 2.62)                    | 0.484 |
| 2-OHE2                            | 0.11 (0, 0.47)                         | 0.73 (0, 1.44)                       | 0.022 |
| 2-MeOE1                           | 0.51 (0.36, 0.67)                      | 0.58 (0.34, 0.92)                    | 0.266 |
| 4-Hydroxylation pathway           | 0.31 (0.04, 0.82)                      | 0.62 (0.11, 1.58)                    | 0.152 |
| 4-OHE1                            | 0.25 (0.69)                            | 0.34 (0.14, 1.43)                    | 0.458 |
| 4-OHE2                            | 0 (0, 0.06)                            | 0 (0, 0.18)                          | 0.113 |
| 4-MeOE1                           | 0 (0, 0.01)                            | 0 (0, 0.01)                          | 0.708 |
| 16-Hydroxylation pathway          | 3.43 (1.93, 5.64)                      | 4.11 (2.15, 10.42)                   | 0.298 |
| 16α-OHE1                          | 0.54 (0.34, 0.98)                      | 0.68 (0.31, 2.22)                    | 0.226 |
| Estriol                           | 2.71 (1.55, 4.71)                      | 3.11 (1.63, 8.02)                    | 0.396 |
| Total estrogens/estrogen metabolites | 9.25 (7.87, 19.80)                      | 10.17 (8.90, 23.45)                   | 0.108 |

Bold indicates statistical significance, P < 0.05.
Association between hormone receptor status and estrogen metabolism

We next sought to determine the relationship between HR status and the levels of estrogen and their metabolites in premenopausal and postmenopausal patients (Table 4). In premenopausal patients with breast cancer, HR status was positively related to 2-OHE2 level (P=0.028). In contrast, there were no significant differences between HR status and all estrogen metabolites in postmenopausal patients (Supplementary Table 1, see section on supplementary materials given at the end of this article). ROC curve (Fig. 3) showed urinary 2-OHE2 had predictive value for HR status in premenopausal patients, with the optimal cutoffs of 0.21.

| Estrogens and estrogen metabolites | Invasive breast cancer 50th (25th, 75th) | Breast fibroadenoma 50th (25th, 75th) | P  |
|-----------------------------------|------------------------------------------|--------------------------------------|----|
| Parent estrogens                  | 3.14 (1.39, 4.86)                        | 4.45 (2.93, 9.20)                    | 0.464 |
| Estrone                           | 1.81 (0.76, 3.87)                        | 3.11 (1.71, 5.25)                    | 0.488 |
| Estradiol                         | 0.63 (0.31, 1.15)                        | 1.54 (0.92, 3.45)                    | 0.300 |
| 2-Hydroxylation pathway           | 1.09 (0.48, 2.21)                        | 2.30 (1.53, 4.59)                    | **0.028** |
| 2-OHE1                            | 0.24 (0.02, 0.70)                        | 0.83 (0.46, 1.87)                    | **0.029** |
| 2-OHE2                            | 0.32 (0.00, 0.92)                        | 0.89 (0.34, 1.31)                    | **0.006** |
| 2-MeOE1                           | 0.25 (0.14, 0.51)                        | 0.41 (0.26, 0.71)                    | 0.071 |
| 4-Hydroxylation pathway           | 0.53 (0.09, 1.32)                        | 0.87 (0.51, 1.50)                    | **0.027** |
| 4-OHE1                            | 0.45 (0.00, 1.32)                        | 0.44 (0.24, 0.81)                    | 0.539 |
| 4-OHE2                            | 0.00 (0.00, 0.08)                        | 0.13 (0.00, 0.24)                    | <0.001 |
| 4-MeOE1                           | 0.00 (0.00, 0.11)                        | 0.07 (0.00, 0.25)                    | <0.001 |
| 16-Hydroxylation pathway          | 1.08 (0.36, 1.84)                        | 2.45 (0.78, 6.41)                    | 0.297 |
| 16α-OHE1                          | 0.16 (0.06, 0.33)                        | 0.58 (0.23, 1.89)                    | <0.001 |
| Estradiol                         | 0.85 (0.26, 1.45)                        | 1.89 (0.45, 5.18)                    | 0.979 |
| Total estrogens/estrogen metabolites | 6.68 (4.15, 10.37)                  | 12.15 (6.86, 24.53)                  | 0.193 |

**Bold** indicates statistical significance, *P* < 0.05.
Discussion

Estrogen metabolism is the cumulative interaction of multiple pathways under the catalytic activities of numerous estrogen metabolic enzymes, during which a variety of metabolites are produced. Since these metabolites exhibit pro- and antitumorigenic properties, an imbalance in the metabolites produced from these different metabolic pathways may lead to serious physiological changes and ultimately cancer. Therefore, understanding the estrogen metabolic pathways and exploring the mechanism of estrogen metabolism in tumorigenesis are of great importance.

Table 4  Association between hormone receptor status and estrogen metabolism in premenopausal breast cancer patients.

| Estrogens and estrogen metabolites          | HR− 50th (25th, 75th) | HR+ 50th (25th, 75th) | P       |
|--------------------------------------------|-----------------------|-----------------------|---------|
| Parent estrogens                           | 7.10 (4.61, 11.35)    | 5.72 (3.71, 8.38)     | 0.382   |
| Estrone                                    | 5.06 (3.02, 6.13)     | 3.85 (2.57, 4.85)     | 0.282   |
| Estradiol                                  | 2.97 (1.59, 5.22)     | 1.94 (1.36, 3.30)     | 0.365   |
| 2-Hydroxylation pathway                    | 2.64 (1.51, 3.56)     | 1.64 (1.21, 3.73)     | 0.708   |
| 2-OHE1                                     | 1.97 (0.38, 2.79)     | 0.87 (0.48, 2.18)     | 0.606   |
| 2-OHE2                                     | 0.00 (0.00, 0.08)     | 0.28 (0.00, 0.55)     | 0.028   |
| 2-MeOE1                                    | 0.55 (0.41, 0.77)     | 0.44 (0.29, 0.66)     | 0.288   |
| 4-Hydroxylation pathway                    | 0.07 (0.00, 0.40)     | 0.44 (0.16, 0.94)     | 0.066   |
| 4-OHE1                                     | 0.07 (0.00, 0.40)     | 0.34 (0.00, 1.59)     | 0.145   |
| 4-OHE2                                     | 0.00 (0.00, 0.07)     | 0.32 (0.03, 0.88)     | 0.229   |
| 4-MeOE1                                    | 0.00 (0.00, 0.00)     | 0.00 (0.00, 0.00)     | 0.101   |
| 16-Hydroxylation pathway                   | 3.43 (2.38, 5.64)     | 3.22 (1.87, 5.87)     | 0.864   |
| 16α-OHE1                                   | 0.67 (0.44, 1.20)     | 0.51 (0.34, 0.84)     | 0.473   |
| Estriol                                    | 2.71 (1.64, 5.25)     | 2.61 (1.42, 5.32)     | 0.950   |
| Total estrogens/estrogen metabolites       | 15.99 (10.23, 21.28)  | 12.11 (7.72, 22.08)   | 0.876   |

HR−, hormone receptor negative breast cancer; HR+, hormone receptor positive breast cancer. Bold indicates statistical significance, P < 0.05.
importance to the effective prevention and treatment of breast cancer.

Estrogen metabolism involves a homeostatic state of active and inactive pathways. Aromatization of androstenedione and testosterone is catalyzed by cytochrome P450 (CYP) enzymes, yielding E1 and E2, respectively (28, 29, 30). Following the conversion from estradiol to estrone in the C17 position, hydroxylation occurs at the C2, C4, or C16 positions of estrone to form A-ring and D-ring metabolites (31), including 2-OHE1, 4-OHE1, 16α-OHE1, and estriol. Previous studies have found that 4-OHE1 has a longer half-life in vivo than 2-OHE1 and is more easily oxidized into quinones, which physically bind to DNA, increasing the probability of DNA replication errors, and therefore increasing the risk for the occurrence of breast cancer.

In this study, we used a rapid HPLC-MS/MS approach to accurately detect and quantify urinary estrogen and estrogen metabolites in patients diagnosed with breast cancer and benign breast disease (due to limited urinary samples from healthy controls). The urine samples of premenopausal and postmenopausal patients were also analyzed. We observed significantly lower levels of urinary 2-OHE2 in premenopausal patients with invasive breast cancer than in patients with breast fibroadenoma. In postmenopausal patients, there was a statistical difference in the levels of 2-OHE1, 2-OHE2, 4-OHE2, 4-MeOE1, and 16α-OHE1 between both groups, showing these metabolites were considerably lower in the patients with breast cancer. The risk of developing breast cancer increased with a decline in the levels of 4-OHE2 and 4-MeOE1. Therefore, the correlation between the levels of estrogen metabolites and breast cancer risk was primarily analyzed in postmenopausal patients.

According to a comprehensive review, 4-OHE2 and 16α-OHE1 are potential oncogenic molecular markers, 2-OHE1 and 2-OHE2 are primary estrogen metabolites, and estrogen methylation products, such as 2-MeOE1 and 4-MeOE1, are potential tumor suppressor molecular markers (15, 32, 33, 34, 35, 36, 37, 38). However, our results showed that the levels of 4-OHE2 (0.00 vs 0.13) and 16α-OHE1 (0.16 vs 0.58) were lower in the patients with breast cancer and that increased 4-OHE2 may inhibit progression of breast cancer. There are a number of possible reasons for this discrepancy: first, the concentrations of estrogens are comparatively low in postmenopausal Asian women, particularly in China, which may influence the results; secondly, the sample size is limited, and large-scale prospective clinical studies are needed to validate our results; thirdly, our analysis included benign controls, rather than a healthy group, which may be inconsistent with the association in the metabolite levels between a malignant and normal group.

Few studies have focused on the association of estrogen metabolites in urine and tumor HR status. This study revealed that in premenopausal patients, 2-OHE2 in HR+ patients was considerably higher than in HR− patients, suggesting that the levels of 2-OHE2 could have different effects on HR+ and HR− breast cancers. Additionally, 2-OHE2 had predictive value for HE status for breast cancer patients, which was potentially attributed to the hypothesis that 2-OHE2 could promote HR+ breast cancer by binding with the HR to enhance nuclear mitosis of tumor cells. However, in postmenopausal patients, there was no difference between HR+ and HR− patients in estrogen and estrogen metabolites.

In summary, estrogen metabolism was associated with breast cancer risk in both premenopausal and postmenopausal women, and the level of 2-OHE2 could be an important factor for HR+ breast cancer.

Figure 3
The ROC curve of urinary 2-OHE2 (area under curve = 0.718, P = 0.037) for hormone receptor status in premenopausal patients.

Supplementary materials
This is linked to the online version of the paper at https://doi.org/10.1530/EC-21-0226.
Endocrinology 2006 147 4132–4150. (https://doi.org/10.1210/en.2006-0113)
14 Kono S, Merriam GR, Brandon D, Loriaux DL, Lipsett MB & Fujino T. Radioimmunoassay and metabolic clearance rate of catecholestrogens, 2-hydroxyestrone and 2-hydroxyestradiol in man. Journal of Steroid Biochemistry 1983 19 627–633. (https://doi.org/10.1016/0022-4731(83)90228-5)
15 Cavaliere F, Feenkel K, Lieder JG, Rogn E & Boy D. Estrogens as endogenous genotoxic agents — DNA adducts and mutations. Journal of the National Cancer Institute: Monographs 2000 27 75–93. (https://doi.org/10.1093/oxfordjournals.jncimonographs.a024247)
16 Yucel K, Abusoglu S & Unlu A. Comparison of immunoassay and liquid chromatography-tandem mass spectrometry methods in the measurement of serum androstenedione levels. Clinical Laboratory 2018 64 69–75. (https://doi.org/10.7754/Clin.Lab.2017.170612)
17 Faupel-Badger JM, Fuhrman BJ, Xu X, Falk RT, Keeler LK, Veenstra TD, Hoover RN & Ziegler RG. Comparison of liquid chromatography-tandem mass spectrometry, RIA, and ELISA methods for measurement of urinary estrogens. Cancer Epidemiology, Biomarkers and Prevention 2010 19 292–300. (https://doi.org/10.1158/1055-9966.EPI-09-0643)
18 Bradlow HL, Sepkovic DW, Klug T & Osborne MP. Application of an improved ELISA assay to the analysis of urinary estrogen metabolites. Steroids 1998 63 406–413. (https://doi.org/10.1006/sost.1998.2278)
19 McGuinness BJ, Power MJ & Fottrell PF. Radioimmunoassay of 2-hydroxyestrone in urine. Clinical Chemistry 1994 40 80–85. (https://doi.org/10.1093/clinchem/40.1.80)
20 Franke AA, Custer LJ, Morimoto Y, Nordt FJ & Maskarinec G. Analysis of urinary estrogens, their oxidized metabolites, and other endogenous steroids by bencktop Orbitrap LC/MS versus traditional quadrupole GC/MS. Analytical and Bioanalytical Chemistry 2011 401 1319–1330. (https://doi.org/10.1007/s00216-011-0164-3)
21 Guo T, Gu J, Soldin OP, Singh RJ & Soldin SJ. Rapid measurement of estrogens and their metabolites in human serum by liquid chromatography-tandem mass spectrometry without derivatization. Clinical Biochemistry 2008 41 736–741. (https://doi.org/10.1016/j.clinbiochem.2008.02.009)
22 Gao WL, Wu LS, Zhi JH, Wu B, Li YZ, Song YC & Cai DZ. Measurement of serum estrone and estrogen metabolites in pre- and postmenopausal women with osteoarthritis using high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. Brazilian Journal of Medical and Biological Research 2015 48 883–884. (https://doi.org/10.1590/1413-8129201522)
23 Carvalho VM. The coming age of liquid chromatography coupled to tandem mass spectrometry in the endocrinology laboratory. Journal of Chromatography: A, Analytical Technologies in the Biomedical and Life Sciences 2012 1283–884 50–58. (https://doi.org/10.1016/j.jchroma.2011.08.027)
24 Rothman MS, Carlson NE, Xu M, Wang C, Swedloff R, Lee P, Goh VH, Ridgway EC & Wierman ME. Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry. Steroids 2011 76 177–182. (https://doi.org/10.1016/j.steroids.2010.10.010)
25 Xu X, Roman JM, Issaq HJ, Keeler LK, Veenstra TD & Ziegler RG. Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography-tandem mass spectrometry. Analytical Chemistry 2007 79 7813–7821. (https://doi.org/10.1021/ac070494j)
26 Xu X, Veenstra TD, Fox SD, Roman JM, Issaq HJ, Falk R, Saavedra JE, Keeler LK & Ziegler RG. Measuring fifteen endogenous estrogens simultaneously in human urine by high-performance liquid chromatography-mass spectrometry. Analytical Chemistry 2005 77 6646–6654. (https://doi.org/10.1021/ac050607c)
27 You J, Shi Y, Li J, Yang X, Liu Z, Zhu W, Wu Z & Xiong J. Rapid quantification of human urinary estrogens and estrogen metabolites
by HPLC mass spectrometry. *Microchemical Journal* 2019 **147** 157–162. (https://doi.org/10.1016/j.microc.2019.03.008)

28 Jefcoate CR, Liehr JG, Santen RJ, Sutter TR, Yager JD, Yue W, Santner SJ, Tekmal R, Demers L, Pauley R, *et al.* Tissue-specific synthesis and oxidative metabolism of estrogens. *Journal of the National Cancer Institute: Monographs* 2000 **27** 95–112. (https://doi.org/10.1093/oxfordjournals.jncimonographs.a024248)

29 Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? *Endocrine Reviews* 2000 **21** 40–54. (https://doi.org/10.1210/edrv.21.1.0386)

30 Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ & Sutter TR. 17beta-Estradiol hydroxylation catalyzed by human cytochrome P450. *PNAS* 1996 **93** 9776–9781. (https://doi.org/10.1073/pnas.93.18.9776)

31 Lippert TH, Seeger H & Mueck AO. *Metabolism of Endogenous Estrogens*. *Estrogens and Antiestrogens I*. Berlin, Heidelberg: Springer, 1999. (https://doi.org/10.1007/978-3-642-58616-3_12)

32 Bradlow HL, Hershcopf RJ, Martucci CP & Fishman J. Estradiol 16 alpha-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. *PNAS* 1985 **82** 6295–6299. (https://doi.org/10.1073/pnas.82.18.6295)

33 Telang NT, Bradlow HL, Kurihara H & Osborne MP. In vitro biotransformation of estradiol by explant cultures of murine mammary tissues. *Breast Cancer Research and Treatment* 1989 **13** 173–181. (https://doi.org/10.1007/BF01806529)

34 Yager JD & Liehr JG. Molecular mechanisms of estrogen carcinogenesis. *Annual Review of Pharmacology and Toxicology* 1996 **36** 203–232. (https://doi.org/10.1146/annurev.pa.36.040196.001223)

35 Zhu BT & Conney AH. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? *Cancer Research* 1998 **58** 2269–2277.

36 Kabat GC, Chang CJ, Sparano JA, Sepkovic DW, Hu XP, Khalil A, Rosenblatt R & Bradlow HL. Urinary estrogen metabolites and breast cancer: a case-control study. *Cancer Epidemiology, Biomarkers and Prevention* 1997 **6** 505–509.

37 Meilahn EN, De Stavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic DW & Kuller LH. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. *British Journal of Cancer* 1998 **78** 1250–1255. (https://doi.org/10.1038/bjc.1998.663)

38 Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schunemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M, *et al.* Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. *Epidemiology* 2000 **11** 635–640. (https://doi.org/10.1097/00001648-200011000-00004)